# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

# E. Applicant:

# F. Proprietary and Established Names:

Omega Laboratories, Inc. Hair Drug Screening Assay for Opiates, Oxycodone and Hydrocodone

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 2 . 3 6 5 0$ , Opiate Test System

2. Classification: Class II

3. Product code: DJG

4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use(s): See Indications for Use below.

2. Indication(s) for use:

The Omega Laboratories Hair Drug Screening Assay (Opiates, Oxycodone and Hydrocodone) is an in vitro diagnostic test that is intended for the qualitative detection of opiates (calibrated with morphine) and oxycodone and hydrocodone (calibrated with oxycodone) at or above $3 0 0 ~ \mathrm { p g / m g }$ in human head and body hair. To confirm a screen positive result, a more specific alternate chemical method, such as Gas Chromatography/Mass Spectrometry (GC/MS) operating in the selected ion monitoring (SIM) mode is the preferred method with deuterated internal standards. Professional judgment should be applied to any drug of abuse test result, particularly when presumptive positive results are obtained.

This test is intended exclusively for single laboratory use only and is not intended for sale to anyone.

3. Special conditions for use statement(s):

For Over-the-Counter Use

4. Special instrument requirements:

The screening assay is for use with an automated microplate reader capable of measuring at $4 5 0 \mathrm { n m }$ .

For confirmation testing, the sponsor uses an Agilent GC/MS in selected ion monitoring (SIM) mode using deuterated internal standards.

# I. Device Description:

Donor head and body hair samples are collected using the Omega Collection Kit. The Donor Sample is shipped to the Company facility where testing is conducted by trained scientists under the direction of the Laboratory Director.

The assay consists of the following:

• Hair sample collection kit   
• Micro strip plates coated with either anti-morphine mouse monoclonal or antioxycodone rabbit polyclonal antibody, enzyme conjugate (horseradish peroxidase conjugated to morphine or oxycodone), substrate (containing tetramethylbenzidine), an enzyme diluent, and wash solution

• In-house prepared calibrators and controls are used. These are prepared solutions of morphine and oxycodone added to negative hair matrix tubes.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Omega Laboratories Hair Drug Screening Assay for Opiates, Oxycodone and Hydrocodone

2. Predicate 510(k) number(s): k103161

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities and Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Laboratory</td><td rowspan=1 colspan=1>Omega Laboratories</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Indication for/IntendedUse</td><td rowspan=1 colspan=1>Same except for bothhead and body hair</td><td rowspan=1 colspan=1>Intended to be used for theQualitative determination of thepresence of opiates, oxycodoneand hydrocodon in human hairfrom the head.</td></tr><tr><td rowspan=1 colspan=1>Method of Measurement</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Microplate Reader read at 450 nm</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Head and body hair</td><td rowspan=1 colspan=1>Head hair</td></tr><tr><td rowspan=1 colspan=1>Cut-off Concentration</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>300 pg Opiates/mg hair300 pg Oxycodone/mg hair300 pg Hydrocodone/mg hair</td></tr><tr><td rowspan=1 colspan=1>Assay Principal</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>ELISA</td></tr><tr><td rowspan=1 colspan=1>Extraction Method</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Acid-methanol to facilitateextraction of Cocaine from hair.Hair is pulverized into smallsegments prior to acid- methanolextraction, which improvesextraction times without loss ofefficiency</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None referenced.

# L. Test Principle:

The test consists of two parts; a pre-analytical hair treatment procedure (to convert the solid matrix of hair to a measurable liquid matrix) and the screening assay. The screening assay is an Enzyme-Linked ImmunoSorbent Assay (ELISA).

Sample is added to a well of the micro strip plate and enzyme conjugate is added, followed by incubation. During this phase the enzyme-labeled drug conjugate competes with drug in the sample for a limited number of binding sites on the antibody-coated micro wells. The two bind in proportion to their concentrations. A wash solution is applied to remove unbound materials. Enzyme substrate solution containing a chromagen is added. The reaction is stopped with a stop solution and absorbance is read using a plate reader at $4 5 0 \mathrm { n m }$ . A background reading is also taken at $6 3 0 \mathrm { n m }$ . Color intensity is inversely proportional to the amount of drug presented in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: See k103161 for precision/reproducibility information.   
b. Linearity/assay reportable range: Not applicable.   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): See k103161 for calibrator and control materials information, hair sample stability, and shipping study information.   
d. Detection limit: Not applicable.   
e. Analytical specificity:

See k103161 for cross reactivity, interference (structurally related and unrelated compounds), hair treatment, and environmental contamination studies.

In addition to studies conducted in $\mathrm { k } 1 0 3 1 6 1$ , the sponsor performed additional cross reactivity testing on several structurally similar compounds including Buprenorphine, Noroxymorphone, 3-Methoxynaltrexone, Morphine-6-betaglucuronide, Nalmefene, Nalorphine, Naloxone-3-beta-D-glucuronide, Naltrexone, Naltriben. These compounds appeared to contribute to an Opiate or Oxycodone positive ELISA result at $- 5 0 \%$ cutoff, but did not show cross reactivity when tested at concentrations up to $4 0 0 , 0 0 0 \mathrm { p g / m g }$ .

To investigate this discrepancy, cross reactivity was tested at up to 10 fold higher concentrations. Expected results were obtained. The results are summarized in the tables below. The tables below are also included in the device labeling.

Cross reactivity of Opiates ELISA with Structurally Similar Compounds   
\* Unable to generate an assay absorbance equivalent to $3 0 0 \mathrm { p g / m g }$ Opiates cutoff. Highest concentration tested was $4 , 0 0 0 , 0 0 0 \mathrm { p g / m g }$ .   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration ofCompound (pg/mg)Equivalent to 300 pg/mgOpiates Cutoff Control</td><td rowspan=1 colspan=1>Percent Cross-Reactivity (%)</td></tr><tr><td rowspan=1 colspan=1>Morphine-6-β-D-glucuronide</td><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>37.5</td></tr><tr><td rowspan=1 colspan=1>Nalorphine</td><td rowspan=1 colspan=1>8500</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>600000</td><td rowspan=1 colspan=1>0.050</td></tr><tr><td rowspan=1 colspan=1>3-Methoxynaltrexone</td><td rowspan=1 colspan=1>900000</td><td rowspan=1 colspan=1>0.033</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>3000000</td><td rowspan=1 colspan=1>0.010</td></tr><tr><td rowspan=1 colspan=1>Noroxymorphone</td><td rowspan=1 colspan=1>4000000</td><td rowspan=1 colspan=1>0.008</td></tr><tr><td rowspan=1 colspan=1>Nalmefene</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Naloxone-3-β-D-glucuronide</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Naltriben</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>0.00</td></tr></table>

Cross Reactivity of Omega Laboratories, Inc. Oxycodone ELISA with Structurally Similar Compounds   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration ofCompound (pg/mg)Equivalent to 300 pg/mgOxycodone Cutoff Control</td><td rowspan=1 colspan=1>Percent Cross-Reactivity (%)</td></tr><tr><td rowspan=1 colspan=1>Morphine-6-β-D-glucuronide</td><td rowspan=1 colspan=1>31000</td><td rowspan=1 colspan=1>0.97</td></tr><tr><td rowspan=1 colspan=1>Nalorphine</td><td rowspan=1 colspan=1>300000</td><td rowspan=1 colspan=1>0.10</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>3-Methoxynaltrexone</td><td rowspan=1 colspan=1>380000</td><td rowspan=1 colspan=1>0.08</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>50000</td><td rowspan=1 colspan=1>0.60</td></tr><tr><td rowspan=1 colspan=1>Noroxymorphone</td><td rowspan=1 colspan=1>58000</td><td rowspan=1 colspan=1>0.52</td></tr><tr><td rowspan=1 colspan=1>Nalmefene</td><td rowspan=1 colspan=1>300000</td><td rowspan=1 colspan=1>0.10</td></tr><tr><td rowspan=1 colspan=1>Naloxone-3-β-D-glucuronide</td><td rowspan=1 colspan=1>680000</td><td rowspan=1 colspan=1>0.04</td></tr><tr><td rowspan=1 colspan=1>Naltriben</td><td rowspan=1 colspan=1>300000</td><td rowspan=1 colspan=1>0.10</td></tr></table>

\* Unable to generate an assay absorbance equivalent to $3 0 0 \mathrm { p g / m g }$ Oxycodone cutoff. Highest concentration tested was $4 { , } 0 0 0 { , } 0 0 0 \mathrm { p g / m g }$

f. Assay cut-off: See k103161.

2. Comparison studies:

a. Method comparison with predicate device:

Method comparison studies on head hair samples were performed and reported in the predicate submission (k103161). Additional method comparison studies were performed for this current submission with 50 body hair samples. Each tested sample was divided into two aliquots and one was used for screening on the candidate device (ELISA assay) and the other for GC/MS confirmation. Testing was performed on hair samples from different ages, gender, ethnicities and hair color. The combined head hair (performed in k103161) and body hair (this submission) results are shown below:

Opiates Equivalents Summary of Agreement Study Results, Head Hair $\bf ( N { = } 1 7 6 )$ and Body Hair $\mathbf { ( N { = } 5 0 ) }$   

<table><tr><td rowspan=1 colspan=1>ELISATestResult</td><td rowspan=1 colspan=1>Negative byGC/MS</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MS</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below thecutoff and thecutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(Greater that50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>116</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr></table>

GC/MS Summary of Opiates Equivalents Discordant Results $( \mathbf { N } { = } 3 )$   

<table><tr><td>Sample No.</td><td>Screening Cutoff (pg/mg)</td><td>ELISA Test Result (POS/NEG)</td><td>GC/MS Cutoff (pg/mg)</td><td>GC/MS Drug Result (pg/mg)</td></tr><tr><td>16</td><td>300</td><td>POS</td><td>300</td><td>HDC 268</td></tr><tr><td>150</td><td>300</td><td>POS</td><td>300</td><td>HDC 299</td></tr><tr><td>29</td><td>300</td><td>NEG</td><td>300</td><td>HDC 354</td></tr></table>

Oxycodone Summary of Agreement Study Results, Head Hair $\mathbf { ( N { = } 4 8 0 ) }$ ) and Body Hair $\mathbf { ( N { = } 5 0 ) }$ .   

<table><tr><td rowspan=1 colspan=1>ELISATestResult</td><td rowspan=1 colspan=1>Negative byGC/MS</td><td rowspan=1 colspan=1>Less thanhalf thecutoffconcentration byGC/MS</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffand the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(Greater that50% above thecutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>221</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr></table>

$^ { * } \mathrm { O f }$ the 530 samples compared in the Oxycodone assays, 46 ELISA head hair positive samples were negative by GC/MS confirmation for oxycodone but positive for hydrocodone and one head hair test sample was lost during centrifugation reducing the number of test samples reported in the table to 483.

GC/MS Summary of Oxycodone Discordant Results $\mathbf { ( N { = } 8 ) }$   

<table><tr><td colspan="1" rowspan="1">SampleNo.</td><td colspan="1" rowspan="1">ScreeningCutoff(pg/mg)</td><td colspan="1" rowspan="1">ELISA TestResult(POS/NEG)</td><td colspan="1" rowspan="1">GC/MS Cutoff(pg/mg)</td><td colspan="1" rowspan="1">GC/MS DrugResult (pg/mg)</td></tr><tr><td colspan="1" rowspan="1">835334</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 169HDC 167</td></tr><tr><td colspan="1" rowspan="1">EXOP 39</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 131HDC 83</td></tr><tr><td colspan="1" rowspan="1">788840</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 185HDC 29</td></tr><tr><td colspan="1" rowspan="1">787180c</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 229HDC 68</td></tr><tr><td colspan="1" rowspan="1">789526</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 240HDC 49</td></tr><tr><td colspan="1" rowspan="1">872104</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 130HDC 221</td></tr><tr><td colspan="1" rowspan="1">854976</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 255</td></tr><tr><td colspan="1" rowspan="1">800488</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">OXY 298</td></tr></table>

Hydrocodone Summary of Agreement Study Results, Head Hair $\mathbf { ( N { = } 4 8 0 ) }$ ), Body Hair $\mathbf { ( N { = } 5 0 ) }$ .   

<table><tr><td rowspan=1 colspan=1>ELISATestResult</td><td rowspan=1 colspan=1>NegativebyGC/MS</td><td rowspan=1 colspan=1>Less thanhalf thecutoffconcentrationby GC/MS</td><td rowspan=1 colspan=1>Near CutoffNegative(Between50% belowthe cutoff andthe cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and50% abovethe cutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(Greater that50% abovethe cutoffconcentration)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>201</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td></tr></table>

$\ast _ { \mathrm { O f } }$ the 530 samples compared in the HDC assays, 27 ELISA head hair positive samples were negative by GC/MS confirmation for hydrocodone but positive for oxycodone, one head hair test sample was lost during centrifugation and 2 ELISA head hair positive samples were not able to be confirmed by GC/MS which reduced the number of test samples reported here to 500.

GC/MS Summary of Hydrocodone Discordant Results $\bf ( N { = } 1 4 )$   

<table><tr><td rowspan=1 colspan=1>SampleNo.</td><td rowspan=1 colspan=1>ScreeningCutoff (pg/mg)</td><td rowspan=1 colspan=1>ELISA TestResult(POS/NEG)</td><td rowspan=1 colspan=1>GC/MSCutoff(pg/mg)</td><td rowspan=1 colspan=1>GC/MS Drug Result(pg/mg)</td></tr><tr><td rowspan=1 colspan=1>787832</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 403</td></tr><tr><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 313</td></tr><tr><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 334</td></tr><tr><td rowspan=1 colspan=1>835334</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 167OXY 169</td></tr><tr><td rowspan=1 colspan=1>872104</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 221OXY 130</td></tr><tr><td rowspan=1 colspan=1>835981a</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 347</td></tr><tr><td rowspan=1 colspan=1>788840</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 29OXY 185</td></tr><tr><td rowspan=1 colspan=1>789526</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 49OXY 240</td></tr><tr><td rowspan=1 colspan=1>787180c</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 68OXY 229</td></tr><tr><td rowspan=1 colspan=1>EXOP39</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 83OXY 131</td></tr><tr><td rowspan=1 colspan=1>790194</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 204</td></tr><tr><td rowspan=1 colspan=1>849237</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 256</td></tr><tr><td rowspan=1 colspan=1>904316</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 272</td></tr><tr><td rowspan=1 colspan=1>780598</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>HDC 283</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies: a. Clinical Sensitivity: Not applicable.

b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.